- In December 2021, Pfizer had received the emergency use authorization from U.S. Food and (FDA) for Novel COVID-19 oral antiviral drug named PAXLOVID. PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) is approved for emergency use in high-risk adults and children 12 years and older who weigh at least 40 kg
- In December 2021, Cipla Limited had received the Emergency Use Authorization (EUA) permission by Drug Controller General of India (DCGI) for the launch of oral anti-viral COVID drug named Molnupiravir. Molnupiravir is the first oral antiviral to be authorized by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 infection in people who are at high risk of developing severe disease